IART trades 32.0% below Wall Street's consensus target of $20.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IART achieves its forward estimates and maintains a stable P/E multiple of 6.3x. This scenario reflects the blended consensus of 26 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Integra LifeSciences Holdings Corporation (IART) has a Wall Street consensus price target of $20.50, based on estimates from 26 covering analysts. With the stock currently trading at $15.53, this represents a potential upside of +32.0%. The company has a market capitalization of $1.21B.
Analyst price targets range from a low of $19.00 to a high of $25.00, representing a 29% spread in expectations. The median target of $19.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,11 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, IART trades at a trailing P/E of -2.3x and forward P/E of 6.3x. Analysts expect EPS to grow +2750.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 ATRCAtriCure, Inc. | $3.0B | $59.95 | $57.29 | -4.4% | Buy | 560.9x | 19 |
 NTRANatera, Inc. | $56.0B | $390.79 | $335.07 | -14.3% | Buy | — | 28 |
 MMSIMerit Medical Systems, Inc. | $5.2B | $87.07 | $101.88 | +17.0% | Buy | 20.2x | 15 |
 LMATLeMaitre Vascular, Inc. | $1.8B | $80.58 | $115.00 | +42.7% | Buy | 28.1x | 20 |
 GMEDGlobus Medical, Inc. | $10.0B | $73.96 | $98.88 | +33.7% | Buy | 14.8x | 36 |
 AORTArtivion, Inc. | $1.1B | $23.53 | $42.50 | +80.6% | Buy | — | 12 |
 TMDXTransMedics Group, Inc. | $3.0B | $87.00 | $96.86 | +11.3% | Buy | 58.7x | 13 |
 ANGOAngioDynamics, Inc. | $641M | $15.51 | $19.50 | +25.7% | Hold | — | 11 |
Quick answers to the most common questions about buying IART stock.
The consensus Wall Street price target for IART is $20.5, representing 32.0% upside from the current price of $15.53. With 26 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
IART has a consensus rating of "Buy" based on 26 Wall Street analysts. The rating breakdown is mixed, with 11 Hold ratings making up the largest segment. The consensus 12-month price target of $20.5 implies 32.0% upside from current levels.
With a forward P/E of 6.3212x, IART trades at a relatively low valuation. The consensus target of $20.5 implies 32.0% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $25 for IART, while the most conservative target is $19. The consensus of $20.5 represents the median expectation. These targets typically reflect 12-month expectations.
IART is heavily covered by Wall Street, with 26 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 11 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IART stock forecast based on 26 Wall Street analysts shows a consensus price target of $20.5, with estimates ranging from $19 (bear case) to $25 (bull case). The median consensus rating is "Buy".
IART trades at a forward P/E ratio of 6.3x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on IART, with a "Buy" consensus rating and $20.5 price target (32.0% upside). 11 of 26 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IART analyst price targets range from $19 to $25, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.